The breakthrough preclinical study demonstrated that highly optimized dMAbs targeting mouse CTLA-4 protein can be robustly expressed in vivo, and shrank tumors in mice. More importantly, Inovio’s dMAb
Chronocort was not successful in confirming its superiority over conventional treatment in endocrine control over a 24-hour period during the late-stage clinical trial held in Europe. Diurnal Group
The company, founded with seed funding from SV Health investors, raised a total of $30 million from a syndicate of specialist international healthcare investors co-led by SV Health
Hemlibra is now the only prophylactic treatment for people with haemophilia A with and without factor VIII inhibitors that can be administered subcutaneously (under the skin) and at
Empagliflozin was evaluated for its efficacy, safety and tolerability as an adjunctive to insulin in comparison to placebo in the late-stage clinical program, dubbed EASE. The primary efficacy
ALN-AAT02 is Alnylam’s first investigational RNAi therapeutic utilizing the Company’s enhanced stabilization chemistry plus (ESC+) GalNAc-conjugate technology. Alnylam ALN-AAT02 program lead vice president Thomas Hoock said: “We are
Kala Pharmaceuticals chairman, president and CEO Mark Iwicki said: “We are pleased to be partnering with Athyrium and to have their support and confidence in INVELTYS for the
The newly licensed Xonvea, which is a combination of doxylamine and pyridoxine, will be available across the country for women having NVP where conservative management was not successful.
Feraccru already has an approval for the indication in adults in the European Union. In Switzerland, the drug has been approved for the treatment of iron deficiency anaemia
The results were presented today at the annual congress of the International Sepsis Forum in Bangkok. Septic shock is the ultimate complication of sepsis and currently constitutes an
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.